Cervical Cancer Screening Market & Patients-North America: Ken Research

1
Cervical Cancer Screening Market Patients-North
America Ken Research
2
Ken research announced recent publication on,
"Canada, United States Cervical Cancer Screening
Market Patients, By Test Type (Pap Smear HPV
DNA VIA) in North America". This report is built
using data and information sourced from
proprietary databases, primary and secondary
research and in-house analysis by team of
industry experts. Primary sources include
industry surveys and telephone interviews with
industry experts.
3
Secondary sources information and data has been
collected from various printable and
non-printable sources like search engines, News
websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines,
Newspapers, Trade associations, Books, Industry
Portals, Industry Associations and access to more
than 1000 paid databases. It provides a
comprehensive analysis and forecast till 2020.
This report provides a complete analysis of 2
Countries Cervical Cancer Test Market Number of
Cervical Cancer Population. Studied countries in
the report have been studied from 3
viewpoints. Cervical cancer Test Population
(2008-2020) Pap smear test population (HPV DNA
test population 2008-2020) Cervical Cancer
Mortality Population (2001-2011) Cervical Cancer
Test Market (2008-2020) The Pap test finds
changes in the cells of the cervix (the mouth of
the womb) that are not normal. When a female has
a Pap test, she is positioned on an exam table
and a device called a speculum is gently inserted
to open the vagina.
4

• The speculum allows the healthcare provider to
  view the cervix and upper vagina. Once the
  provider can see the cervix, a broom device or
  a brush/spatula combination will be used to
  collect the cells. Cervical cancer is one of the
  most common causes of cancer death for North
  American women. It is estimated that over 4,000
  women in the United States and 400 women in
  Canada die from cervical cancer in 2016. However,
  it is also one of the most preventable types of
  cancer. Pap smear and HPV DNA test are two most
  popular testing methods to diagnose cervical
  cancer cases in North America. United States is
  the leader in North America cervical cancer test
  market. It holds over 90 percent testing
  population share alone, and is likely to maintain
  its position in forecasting period as well due to
  women getting regular Pap tests. The main risk
  factor for developing cervical cancer is the
  sexually transmitted human papilloma virus (HPV)
  that infects the cervix.
• Other risk factors for developing cervical cancer
  include
• Becoming sexually active at a young age having
  many sexual partners, or having a sexual partner
  that has had many sexual partners.

5

• Smoking.
• An immune system weakened from taking drugs
  following a transplant, or having a disease such
  as AIDS.
• The use of birth control pills for a long period
  of time.
• Giving birth to many children.
• Having taken diethylstilbestrol (DES), or being
  the daughter of a mother who took DES.
• Market Segmentation
• This research report categorizes the global
  cervical cancer screening market on the basis of
  type of test, and end users.
• Cervical Cancer Screening Market, by Test
• Pap tests
• HPV test/ Co-testing
• Cervical Cancer Screening Market, y End User
• Hospitals

6

• Laboratories
• Physicians offices and clinics
• Cervical Cancer Screening Market, by Geography
• North America
• Europe
• Asia-Pacific
• RoW (Rest of the World)
• Testing market is estimated to reach USD 8.5
  Billion in 2020, expanding at a CAGR of 5.5 from
  2016 to 2020, due to higher incidence of human
  papilloma virus (HPV) infections worldwide. . Pap
  smear tests and colposcopy contributed to the
  largest share of the global cervical cancer
  diagnostic testing market, while HPV typing
  segment registered highest growth rate. By
  geography, North America dominated the overall
  market growth followed by Europe, while Asia
  Pacific region registered higher growth rate and
  likely continue to the same during the forecast
  period from 2016-2020.

7

• Browse Cervical Cancer Diagnostic Testing Market
  by Test Type (Cervical Biopsy, Colposcopy,
  Endocervical Curettage, HPV Typing, Loop
  electrosurgical procedure, Pap Smear Testing),
  and Imaging Tests for Stage Detection (Computed
  tomography or CAT, Magnetic resonance imaging,
  Positron emission tomography, Chest X-Ray)
  Cervical cancer is one of the most common cancers
  in women worldwide. Cervical cancer occurs when
  abnormal cells on the cervix grow out of control.
  
• A virus called human papillomavirus or HPV causes
  most cervical cancer. The virus spreads through
  sexual contact. It is a malignant tumor of the
  lower most part of the uterus (womb) that can be
  prevented by PAP smear screening and a HPV
  vaccine. Cervical cancer is the fourth-most
  common cause of cancer and the fourth-most common
  cause of deaths from cancer in women. Two major
  types of cervical cancers that are typically
  screened and diagnosed in women include
  adenocarcinoma and squamous cell carcinoma. The
  Pap test is a screening test, not a diagnostic
  test, while other tests include colposcopy (with
  biopsy), endocervical scraping, and cone
  biopsies. Imaging tests such as X-rays, CT scans,
  magnetic resonance imaging (MRI) and positron
  emission tomography (PET) help determine the
  spread of cancer.

8
PAP test is the largest segment of the global
market. However, HPV/co-test will be the
fastest-growing product segment during the
forecast period. This report segments the global
cervical cancer screening market by test, and end
user. Based on type of test, the global market is
segmented into PAP test, and HPV test/co-testing.
Based on end users, the global cervical cancer
diagnosis market is categorized into hospitals,
laboratories, and physicians offices and
clinics. Laboratories segment is the major end
users of the global market in 2014. Major
players operating in the global cervical cancer
diagnostic testing market and included in this
report are Abbott Laboratories, Becton, Dickinson
and Company, Hologic, Inc., F. Hoffmann-La Roche
Ltd., Quest Diagnostics, Inc., QIAGEN N.V.,
Femasys, Inc., Zilico Ltd., Guided Therapeutics,
Inc., and OncoHealth Corp. Growth of this market
is driven by growth in aging female population
and rising prevalence rate of cervical cancer,
high incidence rate of HPV infections, increasing
number of awareness programs for cervical cancer
diagnostic, and government initiatives and
funding.
9
Breakthrough products and technologies, and
significant growth in the HPV test market provide
new growth opportunities to players in the global
market. However, Changes in regulatory guidelines
for cervical cancer screening, and use of HPV
vaccines are the key factors that are limiting
growth of this market. In addition, uncertain
reimbursement scenario is the key market
challenge. Key Factors Considered in the
Report North America Cervical Cancer Market North
America Cervical Cancer Test Market And
Forecast North America Cervical Cancer Pap Smear
Test Market North America Cervical Cancer Hpv Dna
Test Market North America Cervical Cancer Test
Market Share North America Cervical Cancer Hpv
Dna Test Market United States Cervical Cancer
Test Market Us Cervical Cancer Pap Smear Test
Future Outlook Global Cervical Cancer Market
Research
10
For more coverage click on the link below
https//www.kenresearch.com/healthcare/pharmaceut
icals/canada-united-states-cervical-cancer/81992-9
1.html Related linkshttps//www.kenresearch.com
/healthcare/pharmaceuticals/japan-proton-therapy-m
arket-forecast/81991-91.htmlhttps//www.kenresea
rch.com/healthcare/pharmaceuticals/europe-cervical
-cancer-test-market-patients/81990-91.html Contac
t UsKen ResearchAnkur Gupta, Head Marketing
CommunicationsAnkur_at_kenresearch.com91-901537824
9
11
(No Transcript)